Abstract
Introduction: In atezolizumab plus bevacizumab (Atezo/Bev) combination treatment, both drugs act on the immune system. Previously, we reported that immunological changes after Atezo/Bev administration for unresectable hepatocellular carcinoma (uHCC) revealed significant alterations in interleukin (IL)-6, soluble IL-2 receptor, tumor necrosis factor-alpha, and programmed cell death-1 levels. Among these variable factors, serum levels of IL-6 can be easily measured on a commercial basis. Therefore, this study aimed to investigate the utility of serum IL-6 as a predictor of tumor response to Atezo/Bev treatment for uHCC. Method: The study included 44 patients with HCC treated with Atezo/Bev. Blood samples were collected before and 3 weeks after treatment, and tumor response was assessed using contrast-enhanced computed tomography 6 weeks after treatment. Results: Significant changes in serum IL-6 levels were observed in patients treated with Atezo/Bev as first-line therapy but not in those treated with it as second-line or later-line therapy. In patients treated with Atezo/Bev as first-line therapy, serum IL-6 levels increased significantly after treatment in patients with a complete or partial response but not in patients with stable or progressive disease. Furthermore, compared to other tumor markers such as alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein, and des-gamma-carboxyprothrombin, serum IL-6 levels exhibited the highest sensitivity in predicting tumor response during the treatment period. Conclusion: In patients with uHCC treated with Atezo/Bev, serum IL-6 levels could serve as a potential predictor of tumor response. Elevated levels after treatment may indicate a favorable tumor response and prognosis.
Journal Section:
Clinical Study
References
1.
Benson
AB
, D’Angelica
MI
, Abbott
DE
, Anaya
DA
, Anders
R
, Are
C
, et al. Hepatobiliary Cancers, version 2.2021, NCCN Clinical Practice Guidelines in Oncology
. J Natl Compr Canc Netw
. 2021
;19
(5
):541
–65
. 2.
Singal
AG
, Llovet
JM
, Yarchoan
M
, Mehta
N
, Heimbach
JK
, Dawson
LA
, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
. Hepatology
. 2023
;78
(6
):1922
–65
. 3.
Hasegawa
K
, Takemura
N
, Yamashita
T
, Watadani
T
, Kaibori
M
, Kubo
S
, et al. Clinical Practice Guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)
. Hepatol Res
. 2023
;53
(5
):383
–90
. 4.
Ducreux
M
, Abou-Alfa
GK
, Bekaii-Saab
T
, Berlin
J
, Cervantes
A
, de Baere
T
, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
. ESMO Open
. 2022
;8
(3
):101567
. 5.
Kudo
M
. Changing the treatment paradigm for hepatocellular carcinoma using atezolizumab plus bevacizumab combination therapy
. Cancers
. 2021
;13
(21
):5475
. 6.
Salem
R
, Li
D
, Sommer
N
, Hernandez
S
, Verret
W
, Ding
B
, et al. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: results from the IMbrave150 trial
. Cancer Med
. 2021
;10
(16
):5437
–47
. 7.
Park
J-W
, Chen
M
, Colombo
M
, Roberts
LR
, Schwartz
M
, Chen
P-J
, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
. Liver Int
. 2015
;35
(9
):2155
–66
. 8.
Kudo
M
. Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma
. Cancers
. 2020
;12
(5
):1089
. 9.
Cha
E
, Wallin
J
, Kowanetz
M
. PD-L1 inhibition with MPDL3280A for solid tumors
. Semin Oncol
. 2015
;42
(3
):484
–7
. 10.
Nagai
H
, Mukozu
T
, Matsui
D
, Kanekawa
T
, Kanayama
M
, Wakui
N
, et al. Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma
. Clin Dev Immunol
. 2012
;2012
:607851
. 11.
Nagai
H
, Mukozu
T
, Kobayashi
K
, Nogami
A
, Nagumo
H
, Mohri
K
, et al. Lenvatinib might induce activation of host immunity in patients with hepatocellular carcinoma
. Oncology
. 2023
;101
(1
):32
–40
. 12.
Nagai
H
, Mukozu
T
, Kanekawa
T
, Matsui
T
, Kanayama
M
, Wakui
N
, et al. Influence of etiology on host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy
. Hepatogastroenterology
. 2013
;60
(124
):858
–63
. 13.
Kobayashi
K
, Nagai
H
, Matsui
T
, Matsuda
T
, Higai
K
. Importance of atezolizumab plus bevacizumab combination treatment as first-line therapy for immunological changes in patients with unresectable hepatocellular carcinoma
. Anticancer Res
. 2023
;43
(10
):4601
–9
. 14.
Schmidt
N
, Thimme
R
. Role of immunity in pathogenesis and treatment of hepatocellular carcinoma
. Dig Dis
. 2016
;34
(4
):429
–37
. 15.
Harding
JJ
, El Dika
I
, Abou-Alfa
GK
. Immunotherapy in hepatocellular carcinoma: primed to make a difference
. Cancer
. 2016
;122
(3
):367
–77
. 16.
Gao
Q
, Qiu
S-J
, Fan
J
, Zhou
J
, Wang
X-Y
, Xiao
Y-S
, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection
. J Clin Oncol
. 2007
;25
(18
):2586
–93
. 17.
Wada
Y
, Nakashima
O
, Kutami
R
, Yamamoto
O
, Kojiro
M
. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration
. Hepatology
. 1998
;27
(2
):407
–14
. 18.
Nagai
H
, Mukozu
T
, Matsui
T
, Mohri
K
, Nagumo
H
, Yoshimine
N
, et al. Remaining issues related to serum cytokines in patients with unresectable hepatocellular carcinoma treated by atezolizumab plus bevacizumab combination treatment
. Oncology
. 2024
. 828
–40
. 19.
Kishimoto
T
. The biology of interleukin-6
. Blood
. 1989
;74
(1
):1
–10
. 20.
Myojin
Y
, Kodama
T
, Sakamori
R
, Maesaka
K
, Matsumae
T
, Sawai
Y
, et al. Interleukin-6 is a circulating prognostic biomarker for hepatocellular carcinoma patients treated with combined immunotherapy
. Cancers
. 2022
;14
(4
):883
. 21.
Lencioni
R
, Llovet
JM
. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
. Semin Liver Dis
. 2010
;30
(1
):52
–60
. 22.
Llovet
JM
, Di Bisceglie
AM
, Bruix
J
, Kramer
BS
, Lencioni
R
, Zhu
AX
, et al. Design and endpoints of clinical trials in hepatocellular carcinoma
. J Natl Cancer Inst
. 2008
;100
(10
):698
–711
. 23.
Yang
H
, Kang
B
, Ha
Y
, Lee
SH
, Kim
I
, Kim
H
, et al. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
. JHEP Rep
. 2023
;5
(4
):100672
. 24.
Shakiba
E
, Ramezani
M
, Sadeghi
M
. Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis
. Clin Exp Hepatol
. 2018
;4
(3
):182
–90
. 25.
Hayakawa
Y
, Tsuchiya
K
, Kurosaki
M
, Yasui
Y
, Kaneko
S
, Tanaka
Y
, et al. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
. Invest New Drugs
. 2022
;40
(2
):392
–402
. 26.
Gao
X
, Zhao
R
, Ma
H
, Zuo
S
. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
. BMC Cancer
. 2023
;23
(1
):635
. 27.
Presta
LG
, Chen
H
, O’Connor
SJ
, Chisholm
V
, Meng
YG
, Krummen
L
, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
. Cancer Res
. 1997
;57
(20
):4593
–9
.28.
Willett
CG
, Boucher
Y
, di Tomaso
E
, Duda
DG
, Munn
LL
, Tong
RT
, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
. Nat Med
. 2004
;10
(2
):145
–7
. 29.
Gabrilovich
D
, Ishida
T
, Oyama
T
, Ran
S
, Kravtsov
V
, Nadaf
S
, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
. Blood
. 1998
;92
(11
):4150
–66
. 30.
Oyama
T
, Ran
S
, Ishida
T
, Nadaf
S
, Kerr
L
, Carbone
DP
, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells
. J Immunol
. 1998
;160
(3
):1224
–32
. 31.
Goel
S
, Duda
DG
, Xu
L
, Munn
LL
, Boucher
Y
, Fukumura
D
, et al. Normalization of the vasculature for treatment of cancer and other diseases
. Physiol Rev
. 2011
;91
(3
):1071
–121
. 32.
Shrimali
RK
, Yu
Z
, Theoret
MR
, Chinnasamy
D
, Restifo
NP
, Rosenberg
SA
. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer
. Cancer Res
. 2010
;70
(15
):6171
–80
. 33.
Chonov
DC
, Ignatova
MMK
, Ananiev
JR
, Gulubova
MV
. IL-6 activities in the tumour microenvironment. Part 1
. Open Access Maced J Med Sci
. 2019
;7
(14
):2391
–8
. 34.
Kimura
A
, Kishimoto
T
. IL-6: regulator of Treg/Th17 balance
. Eur J Immunol
. 2010
;40
(7
):1830
–5
. 35.
Hsieh
C-Y
, Chen
C-A
, Huang
C-Y
, Chang
M-C
, Lee
C-N
, Su
Y-N
, et al. IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways
. Mol Ther
. 2007
;15
(10
):1890
–7
. 36.
Moran
DM
, Mattocks
MA
, Cahill
PA
, Koniaris
LG
, McKillop
IH
. Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway
. J Surg Res
. 2008
;147
(1
):23
–33
. 37.
McLoughlin
RM
, Jenkins
BJ
, Grail
D
, Williams
AS
, Fielding
CA
, Parker
CR
, et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation
. Proc Natl Acad Sci USA
. 2005
;102
(27
):9589
–94
. 38.
Watson
C
, Whittaker
S
, Smith
N
, Vora
AJ
, Dumonde
DC
, Brown
KA
. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes
. Clin Exp Immunol
. 1996
;105
(1
):112
–9
. 39.
Teague
TK
, Marrack
P
, Kappler
JW
, Vella
AT
. IL-6 rescues resting mouse T cells from apoptosis
. J Immunol
. 1997
;158
(12
):5791
–6
. 40.
Ayroldi
E
, Zollo
O
, Cannarile
L
, D’Adamio
F
, Grohmann
U
, Delfino
DV
, et al. Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death
. Blood
. 1998
;92
(11
):4212
–9
. 41.
Castell
JV
, Gomez-Lechon
MJ
, David
M
, Fabra
R
, Trullenque
R
, Heinrich
PC
. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6
. Hepatology
. 1990
;12
(5
):1179
–86
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
